Actively Recruiting

Age: 19Years - 60Years
All Genders
Healthy Volunteers
ID05922176

Biomarker Screening for Immunotherapy Response Evaluation Using Microneedle Patch in Patients with Allergic Rhinitis

Led by Yonsei University · Updated on 2025-03-11

30

Participants Needed

1

Research Sites

59 weeks

Total Duration

On this page

Sponsors

Y

Yonsei University

Lead Sponsor

K

Korea Health Industry Development Institute

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are studying allergic rhinitis, a condition where the nasal lining overreacts to allergens like house dust mites, causing symptoms such as sneezing, runny nose, and congestion. This research focuses on improving immunotherapy, a treatment that aims to change the course of allergic diseases by gradually increasing tolerance to allergens. The study also explores a new method using a microneedle patch to collect skin samples with minimal pain, aiming to identify biomarkers that predict and evaluate response to immunotherapy. Participants include adults aged 19 to 60 with moderate to severe allergic rhinitis caused by house dust mites and a control group without allergic or skin diseases. The study involves evaluating clinical indicators and collecting skin and blood samples before and 4 to 6 months after immunotherapy. The microneedle patch collects skin factors painlessly by penetrating the skin's outer layer for 5 minutes. Immunotherapy types studied include subcutaneous injections, sublingual tablets, and percutaneous treatments. Participants will undergo symptom evaluations using questionnaires and immunological tests before and after about 4 months of treatment. Blood and skin samples are collected to analyze immune responses using RNA transcriptomic profiling and other markers. Researchers monitor changes in immune indicators and compare responses across different immunotherapy types. The total observation period includes baseline and follow-up assessments 4 to 6 months later, with safety and efficacy monitored throughout.

CONDITIONS

Brief Title

Biomarker Screening for Immunotherapy Response Evaluation Using Microneedle Patch in Patients with Allergic Rhinitis

Who Can Participate

Age: 19Years - 60Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged 19 to 60 with allergic rhinitis caused by American house dust mite confirmed by allergy tests (MAST ≥ Class 3 or ImmunoCAP® ≥3.5 kUA/L)
  • Moderate to severe persistent rhinitis according to ARIA guidelines
  • Signed written consent after understanding the study purpose and procedures
  • Adults 19 years or older without skin or allergic diseases for control group
  • Consent to provide human-derived samples and voluntary agreement to participate
Not Eligible

You will not qualify if you...

  • Taking drugs that may affect efficacy evaluation unless stable during the study
  • Use of other clinical trial drugs, biologics, or biological equivalence test drugs within six months
  • Presence of skin disease or tattoo at the patch application site
  • Receiving immunosuppressive or systemic steroid therapy for inflammatory skin diseases
  • Allergic diseases such as atopic dermatitis, allergic asthma, or rhinitis in control group
  • Voluntary refusal or incomplete consent after IRB approval
  • Any other reasons deemed inappropriate for participation by the investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Monitoring

Duration - Up to 1 day

Participants undergo evaluation of clinical indicators and sample collection before immunotherapy to assess baseline immune responses.

1 visit (in-person)

Long-term Monitoring

Duration - 4 to 6 months

Participants receive immunotherapy for about 4 months with follow-up evaluation of clinical indicators and sample collection to monitor immunological changes and treatment response.

1 visit before and 1 visit after immunotherapy

Trial Site Locations

Total: 1 location

1

Yonsei University Health System, Severance Hospital

Seoul, South Korea, 03722

Actively Recruiting

Loading map...

Research Team

K

Kyung Hee Park

I

Im Shin

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Similar Trials

Efficacy and Safety of Subcutaneous Immunotherapy for Rhinit...

Rhinitis, Allergic

Actively Recruiting

32 locations

Prospective, Multicenter, Randomized, Double-blind, Placebo-...

Rhinitis, Allergic

Actively Recruiting

32 locations

Prospective Multicenter Double-Blind Placebo-Controlled Tria...

Rhinitis, Allergic

Actively Recruiting

27 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here